For the Inventor, By the Inventor

Enter inventor name

Wollerau, Switzerland

Pablo Umana

USPTO Granted Patents = 85 (Patent Applications = 141)

CIPO Patents = 21 (Patent Applications = 51)

EPO Patents = 71 (Patent Applications = 85)

Average Co-Inventor Count = 7.0

ph-index = 17

Forward Citations = 900(Granted Patents)

Forward Citations (Not Self Cited) = 582(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Zurich, CH (2011 - 2018)
Waedenswil, CH (2018 - 2022)
Wollerau, CH (2014 - 2024)
Schlieren, CH (2019 - 2024)

Company Filing History:

39 out of 4,945

Hoffmann-la Roche Inc.

Roche Glycart Ag

Glycart Biotechnology Ag

Roche Glyeart Ag

7. 1 out of 3,684

Bristol-myers Squibb Compnay

8. 1 out of 832,843

Other

patents

Years Active: 2011-2025

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Cancer Treatment

Tumor Necrosis Factor

Bispecific Antibodies

T Cell Activation

Immunoconjugates

Interleukin-2 Fusion Proteins

Targeted Therapy

Anti-FAP Antibodies

HER2-Targeting

Combination Therapy

Polynucleotides

NKG2D Antibodies

85 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

2. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

3. 12281153 - Combination therapy with targeted 4-1BB (CD137) agonists (2025-04-21),

4. 12275794 - Bispecific antigen binding molecules comprising anti-FAP clone 212 (2025-04-14),

5. 12258371 - Stabilized immunoglobulin domains (2025-03-25),

6. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

7. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

8. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

9. 12103982 - T cell activating bispecific antigen binding molecules (2024-10-01),

10. 12065478 - HER2-targeting antigen binding molecules comprising 4-1BBL (2024-08-20),

11. 12023368 - Immunoconjugates (2024-07-02),

12. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

13. 11865082 - Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 (2024-01-09),

14. 11827711 - Antibodies binding to NKG2D (2023-11-28),

15. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),

Title: Inventor Pablo Umana - Revolutionizing Technology in Wollerau

Introduction: Pablo Umana is a visionary inventor based in Wollerau, Switzerland, known for his groundbreaking contributions to the field of technology.

Latest Patents: Pablo Umana holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Pablo Umana has worked with leading tech companies to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Pablo Umana has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Pablo Umana's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true pioneer in the field of inventions, with a lasting legacy that continues to inspire future generations.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…